

**AMENDMENTS TO THE CLAIMS**

1. (Currently Amended) A method for treating a subject afflicted with atrial tachyarrhythmia comprising administering to the subject a therapeutically effective amount of an agent which inhibits protein kinase A (PKA) phosphorylation of a type 2 ryanodine receptor (RyR2) in the subject's heart, thereby treating the subject, wherein the agent is a derivative of 1,4-benzothiazepine.

2. (Currently Amended) The method of claim 1, wherein PKA phosphorylation of the RyR2 receptor causes dissociation of a FKBP12.6 ~~binding protein~~ from the RyR2 receptor.

3. The method of claim 1, wherein the atrial tachyarrhythmia is an atrial fibrillation or a supraventricular tachyarrhythmia.

4. (Currently Amended) A method for treating a subject afflicted with atrial tachyarrhythmia comprising administering to the subject a therapeutically effective amount of an agent which inhibits dissociation of a FKBP12.6 ~~binding protein~~ from a type 2 ryanodine (RyR2) receptor in the subject's heart, thereby treating the subject.

5. The method of claim 4, wherein the atrial tachyarrhythmia is an atrial fibrillation or a supraventricular tachyarrhythmia.

6. The method of claim 4, wherein the agent is JTV-519.

7. (Withdrawn) A method for treating a subject afflicted with atrial tachyarrhythmia comprising administering to the subject a therapeutically effective amount of an agent which mimics binding of a FKBP12.6 binding protein to a type 2 ryanodine receptor (RyR2) of the subject's heart, thereby treating the subject.

8. (Withdrawn) The method of claim 7, wherein the atrial tachyarrhythmia is afibrillation or an atrial ventricular tachyarrhythmia.

9. (Withdrawn) An article of manufacture comprising (i) a packaging material having therein an agent which inhibits protein kinase A (PKA) phosphorylation of a type 2 ryanodine receptor (RyR2) and (ii) a label indicating a use for the agent in treating a subject

afflicted with atrial tachyarrhythmia.

10. (Withdrawn) An article of manufacture comprising (i) a packaging material having therein an agent which inhibits dissociation of a FKBP12.6 binding protein from a type 2 ryanodine receptor (RyR2) and (ii) a label indicating a use for the agent in treating a subject afflicted with atrial tachyarrhythmia.

11. (Withdrawn) The article of manufacture of claim 10, wherein the agent is JTV-519.

12. (Withdrawn) An article of manufacture comprising (i) a packaging material having therein an agent which mimics binding of a FKBP12.6 binding protein to a type 2 ryanodine receptor (RyR2) and (ii) a label indicating a use for the agent in treating a subject afflicted with atrial tachyarrhythmia.

13. (Currently Amended) A method for inhibiting the onset of atrial tachyarrhythmia in a subject comprising administering to the subject a prophylactically effective amount of an agent which inhibits protein kinase A (PKA) phosphorylation of a type 2 ryanodine receptor (RyR2) in the subject's heart, thereby inhibiting the onset of an atrial tachyarrhythmia in the subject, wherein the agent is a derivative of 1,4-benzothiazepine.

14. (Currently Amended) The method of claim 13, wherein PKA phosphorylation of the RyR2 receptor causes dissociation of a FKBP12.6 ~~binding protein~~ from the RyR2 receptor.

15. The method of claim 13, wherein the atrial tachyarrhythmia is an atrial fibrillation or a supraventricular tachyarrhythmia.

16. (Currently Amended) A method for inhibiting the onset of atrial tachyarrhythmia in a subject comprising administering to the subject a prophylactically effective amount of an agent which inhibits dissociation of a FKBP12.6 ~~binding protein~~ from a type 2 ryanodine (RyR2) receptor in the subject's heart, thereby inhibiting the onset of atrial tachyarrhythmia in the subject.

17. The method of claim 16, wherein the atrial tachyarrhythmia is an atrial

fibrillation or a supraventricular tachyarrhythmia.

18. The method of claim 16, wherein the agent is JTV-519.

19. (Withdrawn) A method for inhibiting the onset of atrial tachyarrhythmia in a subject comprising administering to the subject a prophylactically effective amount of an agent which mimics binding of a FKBP12.6 binding protein to a type 2 ryanodine receptor (RyR2) of the subject's heart, thereby inhibiting the onset of atrial tachyarrhythmia in the subject.

20. (Withdrawn) The method of claim 19, wherein the atrial tachyarrhythmia is an atrial fibrillation or a supraventricular tachyarrhythmia.

21. (Withdrawn) An article of manufacture comprising (i) a packaging material having therein an agent which inhibits protein kinase A (PKA) phosphorylation of a type 2 ryanodine receptor (RyR2) and (ii) a label indicating a use for the agent in inhibiting the onset of atrial tachyarrhythmia in a subject.

22. (Withdrawn) An article of manufacture comprising (i) a packaging material having therein an agent which inhibits dissociation of a FKBP12.6 binding protein from a type 2 ryanodine receptor (RyR2) and (ii) a label indicating a use for the agent in inhibiting the onset of atrial tachyarrhythmia in a subject.

23. (Withdrawn) The article of manufacture of claim 22, wherein the agent is JTV-519.

24. (Withdrawn) An article of manufacture comprising (i) a packaging material having therein an agent which mimics binding of a FKBP12.6 binding protein to a type 2 ryanodine receptor (RyR2) and (ii) a label indicating a use for the agent in inhibiting the onset of atrial tachyarrhythmia in a subject.